New study below [1].
There have been some negative posts regarding the potential benefit of Dutasteride [Avodart] against PCa.
Dr Myers used Avodart in men on ADT who nonetheless produced significant levels of dihydrotestosterone [DHT]. (The true target of ADT is DHT - not testosterone [T].) Myers used blood tests to monitor DHT.
My concern with DHT is that it might be made within cancer cells. Normally, DHT is made from T. However, there are alternative pathways not dependent on T. A blood test will not be helpful in identifying intratumoral DHT.
In the new study:
"Meta-analysis was performed with 9 cohorts (1093 specimens) from Gene Expression Omnibus, 16 cohorts (933 specimens) from Oncomine and the TCGA cohort (550 specimens)."
"We found significant up regulation of 5α-reductase type 1 and type 3 in both primary and metastatic PC, together with the down regulation of AKR1C2 in primary PC, contributing to the high intratumoral DHT levels."
Dutasteride inhibits all three isoforms of 5α-reductase (Finasteride only inhibits types 2 & 3.)
... more below.
-Patrick
[1] ncbi.nlm.nih.gov/pubmed/317...
J Steroid Biochem Mol Biol. 2019 Nov 26:105559. doi: 10.1016/j.jsbmb.2019.105559. [Epub ahead of print]
Meta-Analysis of steroid-converting enzymes and related receptors in prostate cancer suggesting novel combined therapies.
Zhang WF1, Li T2, Lin SX3.
Author information
1
Axe Molecular Endocrinology and Nephrology, CHU Research Center and Department of Molecular Medicine, Laval University, 2705 Boulevard Laurier, Quebec City, Quebec G1V 4G2, Canada. Electronic address: wenfa.zhang.1@ulaval.ca.
2
Axe Molecular Endocrinology and Nephrology, CHU Research Center and Department of Molecular Medicine, Laval University, 2705 Boulevard Laurier, Quebec City, Quebec G1V 4G2, Canada; Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 457 Zhongshan Road, Dalian 116023, China. Electronic address: tang.li.1@ulaval.ca.
3
Axe Molecular Endocrinology and Nephrology, CHU Research Center and Department of Molecular Medicine, Laval University, 2705 Boulevard Laurier, Quebec City, Quebec G1V 4G2, Canada. Electronic address: sxlin@crchul.ulaval.ca.
Abstract
Androgen receptor (AR) signaling is essential for prostate cancer (PC) progression and treatment. Experiments have demonstrated that the intratumoral androgen levels are not affected by circulating androgen levels, but rather modulated by local steroid-converting enzyme activities. The expression modulation status of human steroid-converting enzymes and nuclear receptors are of great promise to identify novel therapeutic targets. Meta-analysis was performed with 9 cohorts (1093 specimens) from Gene Expression Omnibus, 16 cohorts (933 specimens) from Oncomine and the TCGA cohort (550 specimens). We found significant up regulation of 5α-reductase type 1 and type 3 in both primary and metastatic PC, together with the down regulation of AKR1C2 in primary PC, contributing to the high intratumoral DHT levels. The expression of AR in metastatic PC was up regulated, indicating the importance of AR signaling in the progression of this cancer. The down regulations of HSD11B1 and NR3C1 in primary and metastatic PC may diminish the anti-inflammation and anti-proliferation effects of glucocorticoids signaling. Furthermore, the decrease of progesterone receptor (PGR) expression in primary and metastatic PC was also observed, relieving the suppression effect of PGR on PC proliferation. The clinical evidences of the remarkable expression modulation of steroid-converting enzymes and receptors in PC may indicate novel combined treatment against this highly incident cancer.
Copyright © 2019. Published by Elsevier Ltd.
KEYWORDS:
Androgen Receptor; Microarray Analysis; Prostatic Neoplasms; RNA Sequencing
PMID: 31783154 DOI: 10.1016/j.jsbmb.2019.105559